FLUDARABINE Side Effects

6694046-0 | Acute Graft Versus Host Disease, Blood Creatinine Increased, Confusional State, Haemoglobin Decreased, Platelet Count Decreased, Red Blood Cell Schistocytes Present, Sepsis, Thrombotic Microangiopathy
on Apr 09, 2010 Female patient from AUSTRALIA , 20 years of age, was diagnosed with stem cell transplant and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, blood creatinine increased, confusional state, haemoglobin decreased, platelet count decreased, red blood cell schistocytes present, sepsis (What is sepsis?), thrombotic microangiopathy. Fludarabine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6694041-1 | Blood Creatinine Increased, Chronic Graft Versus Host Disease, Convulsion, Device Related Sepsis, Haemoglobin Decreased, Platelet Count Decreased, Red Blood Cell Schistocytes Present, Thrombotic Microangiopathy
Patient was taking Fludarabine (View Usage). Patient had the following side effects: blood creatinine increased, chronic graft versus host disease, convulsion, device related sepsis, haemoglobin decreased, platelet count decreased, red blood cell schistocytes present, thrombotic microangiopathy on Apr 09, 2010 from AUSTRALIA Additional patient health information: Male patient , 50 years of age, was diagnosed with stem cell transplant and. Fludarabine dosage: . During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ).

6691442-2 | Chronic Lymphocytic Leukaemia Transformation, Escherichia Bacteraemia, Infection, Oral Candidiasis, Oral Herpes, Pyrexia
Adverse event was reported on Apr 07, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: 2 Cycles Fludarabine And Cyclophosphamide) was diagnosed with chronic lymphocytic leukaemia and. Location: TURKEY , 56 years of age, After Fludarabine was administered, patient had the following side effects: chronic lymphocytic leukaemia transformation, escherichia bacteraemia, infection (What is infection?), oral candidiasis, oral herpes, pyrexia. During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), CYCLOPHOSPHAMIDE (2 Cycles Of Cyclophosphamide And Fludarabine) (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (Cyclophosphamide-vincristine-prednisolone) (View Vincristine Review and Vincristine Label ), MITOXANTRONE (Fludarabine-mitoxantrone-dexamethasone) (View Mitoxantrone Review and Mitoxantrone Label ), DEXAMETHASONE (Fludarabine-mitoxantrone-dexamethasone) (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6691436-7 | Brain Neoplasm Malignant, Dizziness, Nausea
on Apr 06, 2010 Male patient from SWEDEN , 60 years of age, weighting 191.8 lb, was diagnosed with chronic lymphocytic leukaemia, prophylaxis, pulmonary embolism (What is pulmonary embolism?) and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: brain neoplasm malignant, dizziness (What is dizziness?), nausea (What is nausea?). Fludarabine dosage: Cycle 4. During the same period patient was treated with ALEMTUZUMAB (Total Daily Dose: 30 Mg) (View Alemtuzumab Review and Alemtuzumab Label ), CYCLOPHOSPHAMIDE (Cycle 4) (View Cyclophosphamide Review and Cyclophosphamide Label ), VALACICLOVIR (View Valaciclovir Review and Valaciclovir Label ), SULPHAMETHOXAZOLE (View Sulphamethoxazole Review and Sulphamethoxazole Label ), DALTEPARIN (View Dalteparin Review and Dalteparin Label ). Patient was hospitalized.


6689729-2 | Brain Neoplasm Malignant, Dizziness, Nausea
on Apr 06, 2010 Male patient from SWEDEN , 60 years of age, weighting 191.8 lb, was diagnosed with chronic lymphocytic leukaemia, prophylaxis, pulmonary embolism (What is pulmonary embolism?) and was treated with Fludarabine (View Usage). Patient had the following side effects: brain neoplasm malignant, dizziness (What is dizziness?), nausea (What is nausea?). Fludarabine dosage: Cycle 4. During the same period patient was treated with ALEMTUZUMAB (Total Daily Dose: 30 Mg) (View Alemtuzumab Review and Alemtuzumab Label ), CYCLOPHOSPHAMIDE (Cycle 4) (View Cyclophosphamide Review and Cyclophosphamide Label ), VALACICLOVIR (View Valaciclovir Review and Valaciclovir Label ), SULPHAMETHOXAZOLE (View Sulphamethoxazole Review and Sulphamethoxazole Label ), DALTEPARIN (View Dalteparin Review and Dalteparin Label ). Patient was hospitalized.

6688015-4 | Acute Graft Versus Host Disease In Skin, Disseminated Intravascular Coagulation, Microangiopathy, Staphylococcal Sepsis
Patient was taking Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: acute graft versus host disease in skin, disseminated intravascular coagulation, microangiopathy, staphylococcal sepsis on Apr 09, 2010 from JAPAN Additional patient health information: Female patient , 24 years of age, was diagnosed with stem cell transplant, prophylaxis against graft versus host disease and. Fludarabine dosage: . During the same period patient was treated with MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (Short-term Methotrexate) (View Methotrexate Review and Methotrexate Label ).

6688003-8 | Graft Versus Host Disease, Haemolysis
Adverse event was reported on Apr 09, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with stem cell transplant, prophylaxis against graft versus host disease and. Location: UNITED STATES , 58 years of age, Patient experienced the following unwanted or unexpected effects: graft versus host disease, haemolysis. During the same period patient was treated with MELPHALAN HYDROCHLORIDE (View Melphalan Hydrochloride Review and Melphalan Hydrochloride Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MOFETIL MYCOPHENOLATE (View Mofetil Mycophenolate Review and Mofetil Mycophenolate Label ).

6687995-0 | Acute Graft Versus Host Disease In Skin, Adenoviral Haemorrhagic Cystitis, Cytomegalovirus Test Positive, Febrile Neutropenia, Human Herpes Virus 6 Serology Positive, Interstitial Lung Disease, Multi-organ Failure, Pulmonary Alveolar Haemorrhage
on Apr 09, 2010 Male patient from JAPAN , 50 years of age, was diagnosed with prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). Patient had the following side effects: acute graft versus host disease in skin, adenoviral haemorrhagic cystitis, cytomegalovirus test positive, febrile neutropenia, human herpes virus 6 serology positive, interstitial lung disease, multi-organ failure, pulmonary alveolar haemorrhage. Fludarabine dosage: . During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), HUMAN GRANULOCYTE COLONY STIMULATING FACTOR (From Day 1) (View Human Granulocyte Colony-stimulating Factor Review and Human Granulocyte Colony-stimulating Factor Label ), HUMAN GRANULOCYTE COLONY STIMULATING FACTOR (View Human Granulocyte Colony-stimulating Factor Review and Human Granulocyte Colony-stimulating Factor Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXAT (Short-term) (View Methotrexat Review and Methotrexat Label ), HEPARIN (View Heparin Review and Heparin Label ), IMMUNE GLOBULIN NOS (From Day -1 To Day 100) (View Immune Globulin Nos Review and Immune Globulin Nos Label ).

6687994-9 | Blood Creatine Phosphokinase Increased, Coagulopathy, Dyspnoea, Hepatic Cirrhosis, Hepatitis B, Hyperbilirubinaemia, Hypotension, Hypoxia, Lactic Acidosis
on Apr 09, 2010 Male patient from UNITED STATES , 54 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: blood creatine phosphokinase increased, coagulopathy, dyspnoea, hepatic cirrhosis, hepatitis b (What is hepatitis b?), hyperbilirubinaemia, hypotension, hypoxia, lactic acidosis. Fludarabine dosage: Four Cycles. During the same period patient was treated with RITUXAN (Four Cycles) (View Rituxan Review and Rituxan Label ), CYTOXAN (Four Cycles) (View Cytoxan Review and Cytoxan Label ). Patient was hospitalized.

6687943-3 | Febrile Neutropenia, Pulmonary Mass, Rash
Patient was taking Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, pulmonary mass, rash (What is rash?) on Apr 06, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 41 years of age, was diagnosed with chronic myeloid leukaemia and. Fludarabine dosage: . During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), DASATINIB (View Dasatinib Review and Dasatinib Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ).

6687880-4 | Cerebral Atrophy, Hallucination, Hypoaesthesia, Malignant Melanoma, Muscular Weakness, Neurotoxicity, Ocular Toxicity, Optic Atrophy
Adverse event was reported on Mar 23, 2010 by a Female patient taking Fludarabine (View Usage) (Dosage: Two Cycles In Standard Doses For 5 Days) was diagnosed with bone marrow conditioning regimen and. Location: UNITED STATES , 48 years of age, Patient had the following side effects: cerebral atrophy, hallucination, hypoaesthesia, malignant melanoma, muscular weakness, neurotoxicity, ocular toxicity, optic atrophy. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), PROLEUKIN (Systemic) (View Proleukin Review and Proleukin Label ).

6682513-5 | Brain Neoplasm Malignant, Dizziness, Nausea
on Mar 26, 2010 Male patient from NETHERLANDS , 60 years of age, weighting 191.8 lb, was diagnosed with chronic lymphocytic leukaemia, prophylaxis, pulmonary embolism (What is pulmonary embolism?) and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: brain neoplasm malignant, dizziness (What is dizziness?), nausea (What is nausea?). Fludarabine dosage: Cycle 4. During the same period patient was treated with ALEMTUZUMAB (Total Daily Dose: 30 Mg) (View Alemtuzumab Review and Alemtuzumab Label ), CYCLOPHOSPHAMIDE (Cycle 4) (View Cyclophosphamide Review and Cyclophosphamide Label ), VALACICLOVIR (View Valaciclovir Review and Valaciclovir Label ), SULPHAMETHOXAZOLE (View Sulphamethoxazole Review and Sulphamethoxazole Label ), DALTEPARIN (View Dalteparin Review and Dalteparin Label ). Patient was hospitalized.

6678851-2 | Catheter Site Erythema, Epistaxis, Febrile Neutropenia, Fungal Rhinitis, Herpes Simplex, Mouth Ulceration, Nasal Septum Ulceration, Staphylococcal Bacteraemia
on Mar 19, 2010 Male patient from UNITED STATES , 59 years of age, was diagnosed with acute myeloid leukaemia and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: catheter site erythema, epistaxis, febrile neutropenia, fungal rhinitis, herpes simplex (What is herpes simplex?), mouth ulceration, nasal septum ulceration, staphylococcal bacteraemia. Fludarabine dosage: Day 1 To 5 Per Cycle, 2 Cycles In Total. During the same period patient was treated with IDARUBICIN HCL (Day 1 To 5 Per Cycle. 2 Cycles In Total) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), GEMTUZUMAB (1 Dose On Day 8 Per Cycle, 2 Cycles In Total) (View Gemtuzumab Review and Gemtuzumab Label ). Patient was hospitalized.

6674365-4 | Brain Neoplasm Malignant, Dizziness, Nausea
Patient was taking Fludarabine (View Usage). Patient had the following side effects: brain neoplasm malignant, dizziness (What is dizziness?), nausea (What is nausea?) on Mar 26, 2010 from NETHERLANDS Additional patient health information: Male patient , 60 years of age, weighting 191.8 lb, was diagnosed with chronic lymphocytic leukaemia, prophylaxis, pulmonary embolism (What is pulmonary embolism?) and. Fludarabine dosage: Cycle 4. During the same period patient was treated with ALEMTUZUMAB (Total Daily Dose: 30 Mg) (View Alemtuzumab Review and Alemtuzumab Label ), CYCLOPHOSPHAMIDE (Cycle 4) (View Cyclophosphamide Review and Cyclophosphamide Label ), VALACICLOVIR (View Valaciclovir Review and Valaciclovir Label ), SULPHAMETHOXAZOLE (View Sulphamethoxazole Review and Sulphamethoxazole Label ), DALTEPARIN (View Dalteparin Review and Dalteparin Label ). Patient was hospitalized.

6667529-7 | Ataxia, Jc Virus Infection, Mental Status Changes, Progressive Multifocal Leukoencephalopathy
Adverse event was reported on Mar 23, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: Standard-dose, 3 Cycles) was diagnosed with chronic lymphocytic leukaemia and. Location: UNITED STATES , 58 years of age, After Fludarabine was administered, patient had the following side effects: ataxia (What is ataxia?), jc virus infection, mental status changes, progressive multifocal leukoencephalopathy. During the same period patient was treated with RITUXIMAB (4 Doses) (View Rituximab Review and Rituximab Label ).

6667527-3 | Confusional State, Dysarthria, Jc Virus Infection, Personality Change, Progressive Multifocal Leukoencephalopathy
on Mar 23, 2010 Male patient from UNITED STATES , 79 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: confusional state, dysarthria, jc virus infection, personality change, progressive multifocal leukoencephalopathy. Fludarabine dosage: 9 Cycles. During the same period patient was treated with ALEMTUZUMAB (View Alemtuzumab Review and Alemtuzumab Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (6 Cycles) (View Cyclophosphamide Review and Cyclophosphamide Label ), PENTOSTATIN (6 Cycles) (View Pentostatin Review and Pentostatin Label ). Patient was hospitalized.

6643934-X | Encephalopathy, Hypoaesthesia, Leukoencephalopathy, Muscular Weakness, Nervous System Disorder, Neurotoxicity, Visual Acuity Reduced
on Mar 02, 2010 Male patient from UNITED STATES , 48 years of age, was diagnosed with bone marrow transplant (What is bone marrow transplant?) and was treated with Fludarabine (View Usage). Patient had the following side effects: encephalopathy, hypoaesthesia, leukoencephalopathy, muscular weakness, nervous system disorder, neurotoxicity, visual acuity reduced. Fludarabine dosage: 5-day Infusion Of 38.5 Mg/m2 Fludarabine Per Day. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6640335-5 | Anti-platelet Antibody Positive, Autoimmune Thrombocytopenia, Cystitis Haemorrhagic, Ecchymosis, Fungal Infection, Haemorrhage, Petechiae, Rectal Haemorrhage, Refractoriness To Platelet Transfusion
Patient was taking Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: anti-platelet antibody positive, autoimmune thrombocytopenia, cystitis haemorrhagic, ecchymosis, fungal infection (What is fungal infection?), haemorrhage, petechiae, rectal haemorrhage, refractoriness to platelet transfusion on Mar 03, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 51 years of age, was diagnosed with acute myeloid leukaemia, thrombocytopenia and. Fludarabine dosage: Flag-ida Regimen. During the same period patient was treated with CYTARABINE (Flag-ida Regimen) (View Cytarabine Review and Cytarabine Label ), GRANULOCYTE COLONY STIMULATING FACTOR (Flag-ida Regimen) (View Granulocyte-colony Stimulating Factor Review and Granulocyte-colony Stimulating Factor Label ), GRANULOCYTE COLONY STIMULATING FACTOR (Consolidation Flag (without Ida)) (View Granulocyte-colony Stimulating Factor Review and Granulocyte-colony Stimulating Factor Label ), IDARUBICIN HCL (Flag-ida Regimen) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), RED BLOOD CELL TRANSFUSIONS (Multiple) (View Red Blood Cell Transfusions Review and Red Blood Cell Transfusions Label ), PLATELETS (Unselected Random And Hla-matched Plts, Multiple Transfusions) (View Platelets Review and Platelets Label ).

6640301-X | Acute Graft Versus Host Disease In Skin, Cerebral Toxoplasmosis, Diabetes Mellitus
Adverse event was reported on Mar 03, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with stem cell transplant, prophylaxis against graft versus host disease, acute graft versus host disease in skin, diabetes mellitus, infection prophylaxis and. Location: BELGIUM , 61 years of age, Patient experienced the following unwanted or unexpected effects: acute graft versus host disease in skin, cerebral toxoplasmosis, diabetes mellitus. During the same period patient was treated with TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CORTICOSTEROIDS (View Corticosteroids Review and Corticosteroids Label ), INSULIN (View Insulin Review and Insulin Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), PENTAMIDINE ISETHIONATE (View Pentamidine Isethionate Review and Pentamidine Isethionate Label ).

6640232-5 | Acute Graft Versus Host Disease In Skin, Cholecystitis, Cytomegalovirus Infection, Febrile Neutropenia, Neurological Decompensation, Paraparesis
on Mar 03, 2010 Male patient from ITALY , 28 years of age, was diagnosed with stem cell transplant, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). Patient had the following side effects: acute graft versus host disease in skin, cholecystitis, cytomegalovirus infection (What is cytomegalovirus infection?), febrile neutropenia, neurological decompensation, paraparesis. Fludarabine dosage: On Days -6 To -2 Pre-transplant. During the same period patient was treated with TREOSULFAN (On Days -6 To -4 Pre-transplant) (View Treosulfan Review and Treosulfan Label ), RITUXIMAB (On Day -1 Transplant) (View Rituximab Review and Rituximab Label ), ATG FRESENIUS (On Days -4 To -2 Pre-transpalnt) (View Atg-fresenius Review and Atg-fresenius Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (Short Course) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6639434-3 | Megakaryocytes Abnormal, Myelodysplastic Syndrome
on Mar 15, 2010 Male patient from UNITED KINGDOM , 69 years of age, weighting 218.5 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: megakaryocytes abnormal, myelodysplastic syndrome. Fludarabine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ).

6637835-0 | Encephalopathy, Hypoaesthesia, Leukoencephalopathy, Muscular Weakness, Nervous System Disorder, Neurotoxicity, Visual Acuity Reduced
Patient was taking Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: encephalopathy, hypoaesthesia, leukoencephalopathy, muscular weakness, nervous system disorder, neurotoxicity, visual acuity reduced on Mar 02, 2010 from UNITED STATES Additional patient health information: Male patient , 48 years of age, was diagnosed with bone marrow transplant (What is bone marrow transplant?) and. Fludarabine dosage: 5-day Infusion Of 38.5 Mg/m2 Fludarabine Per Day. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6637805-2 | Aphasia, Confusional State, Extensor Plantar Response, Lethargy, Leukoencephalopathy, Neurotoxicity, Pupillary Reflex Impaired
Adverse event was reported on Mar 02, 2010 by a Female patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with multiple myeloma (What is multiple myeloma?) and. Location: UNITED STATES , 58 years of age, Patient had the following side effects: aphasia (What is aphasia?), confusional state, extensor plantar response, lethargy, leukoencephalopathy, neurotoxicity, pupillary reflex impaired. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6637732-0 | Areflexia, Bronchopulmonary Aspergillosis, Coma, Dyspnoea, Fungal Sepsis, Hyporeflexia, Leukoencephalopathy, Neurotoxicity, Renal Failure Acute
on Mar 02, 2010 Female patient from UNITED STATES , 35 years of age, was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: areflexia, bronchopulmonary aspergillosis, coma, dyspnoea, fungal sepsis, hyporeflexia, leukoencephalopathy, neurotoxicity, renal failure acute. Fludarabine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6619449-1 | Bone Marrow Failure, Deep Vein Thrombosis, Herpes Zoster, Multiple Myeloma, Neuroendocrine Carcinoma Of The Skin, Pancytopenia, Staphylococcal Bacteraemia
on Feb 27, 2010 Male patient from UNITED STATES , 71 years of age, was diagnosed with chronic lymphocytic leukaemia, multiple myeloma (What is multiple myeloma?) and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow failure, deep vein thrombosis (What is deep vein thrombosis?), herpes zoster, multiple myeloma (What is multiple myeloma?), neuroendocrine carcinoma of the skin, pancytopenia, staphylococcal bacteraemia. Fludarabine dosage: 5 Cycles. During the same period patient was treated with PREDNISONE (View Prednisone Review and Prednisone Label ), CYCLOPHOSPHAMIDE (5 Cycles) (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXIMAB (5 Cycles) (View Rituximab Review and Rituximab Label ), TRANSFUSION SUPPORT (View Transfusion Support Review and Transfusion Support Label ).

6617862-X | Acute Graft Versus Host Disease In Intestine, Acute Graft Versus Host Disease In Skin, Cytomegalovirus Infection, Transplant Rejection
Patient was taking Fludarabine (View Usage). Patient had the following side effects: acute graft versus host disease in intestine, acute graft versus host disease in skin, cytomegalovirus infection (What is cytomegalovirus infection?), transplant rejection on Feb 24, 2010 from ITALY Additional patient health information: Male patient , child 8 years of age, was diagnosed with bone marrow conditioning regimen and. Fludarabine dosage: For Bmt. During the same period patient was treated with CYCLOPHOSPHAMIDE (For Bmt) (View Cyclophosphamide Review and Cyclophosphamide Label ), ANTI THYMOCYTE GLOBULIN NOS (For Bmt) (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), ANTI THYMOCYTE GLOBULIN NOS (For Pbsc Transplantation 2 Months Later) (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ).

6617593-6 | Acute Graft Versus Host Disease, Diarrhoea Haemorrhagic, Hypertension, Klebsiella Sepsis, Streptococcal Sepsis
Adverse event was reported on Feb 19, 2010 by a Female patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with congenital aplastic anaemia, stem cell transplant, prophylaxis against graft versus host disease and. Location: SAUDI ARABIA , child 2 years of age, weighting 15.43 lb, After Fludarabine was administered, patient had the following side effects: acute graft versus host disease, diarrhoea haemorrhagic, hypertension, klebsiella sepsis, streptococcal sepsis. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), RABBIT ATG (View Rabbit Atg Review and Rabbit Atg Label ), MYCOPHENOLATE MOFETIL (As Used: 20 Mg/kg) (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), METHYLPREDNISOLONE (Total Daily Dose: 1 Mg/kg) (View Methylprednisolone Review and Methylprednisolone Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ).

6615685-9 | Acute Graft Versus Host Disease, Acute Graft Versus Host Disease In Intestine, Diarrhoea Haemorrhagic, Hypertension, Klebsiella Sepsis, Streptococcal Sepsis
on Feb 19, 2010 Female patient from SAUDI ARABIA , child 2 years of age, weighting 15.43 lb, was diagnosed with congenital aplastic anaemia, stem cell transplant, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, acute graft versus host disease in intestine, diarrhoea haemorrhagic, hypertension, klebsiella sepsis, streptococcal sepsis. Fludarabine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), RABBIT ATG (View Rabbit Atg Review and Rabbit Atg Label ), MYCOPHENOLATE MOFETIL (As Used: 20 Mg/kg) (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), METHYLPREDNISOLONE (Total Daily Dose: 1 Mg/kg) (View Methylprednisolone Review and Methylprednisolone Label ), ANTIBIOTICS (View Antibiotics Review and Antibiotics Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ).

6615079-6 | Confusional State, Diplegia, Pyrexia
on Jun 09, 2009 Male patient from AUSTRALIA , 74 years of age, weighting 169.8 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Fludarabine (View Usage). Patient had the following side effects: confusional state, diplegia, pyrexia. Fludarabine dosage: . During the same period patient was treated with MABTHERA (View Mabthera Review and Mabthera Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), ZOCOR (View Zocor Review and Zocor Label ), HYDROCORTISONE (View Hydrocortisone Review and Hydrocortisone Label ).

6599281-8 | C-reactive Protein Increased, Exophthalmos, Headache, Nausea, Neutropenia, Orbital Apex Syndrome, Periorbital Oedema, Pyrexia
Patient was taking Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: c-reactive protein increased, exophthalmos, headache (What is headache?), nausea (What is nausea?), neutropenia, orbital apex syndrome, periorbital oedema, pyrexia on Feb 16, 2010 from SWEDEN Additional patient health information: Female patient , 64 years of age, was diagnosed with stem cell transplant, immunosuppression and. Fludarabine dosage: . During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), THYMOGLOBULIN (View Thymoglobulin Review and Thymoglobulin Label ), TACROLIMUS (Trough Level 50 Ng/ml) (View Tacrolimus Review and Tacrolimus Label ), SIROLIMUS (5 Ng/ml)) (View Sirolimus Review and Sirolimus Label ), CYCLOSPORINE (Trough Level 200-300 Ng/ml) (View Cyclosporine Review and Cyclosporine Label ).

6593252-3 | Dyspnoea, Oxygen Saturation Decreased, Respiratory Rate Increased, Tachycardia
Adverse event was reported on Feb 09, 2010 by a Female patient taking Fludarabine (View Usage) (Dosage: 25 Mg/m2/kg) was diagnosed with colorectal cancer (What is colorectal cancer?) and. Location: UNITED KINGDOM , 46 years of age, Patient experienced the following unwanted or unexpected effects: dyspnoea, oxygen saturation decreased, respiratory rate increased, tachycardia. During the same period patient was treated with MFEZ (1.32 10e10 T-cells) (View Mfez Review and Mfez Label ), CYCLOPHOSPHAMIDE (60mg/m2/kg; Dose 5100mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), INTERLEUKIN 2 (7 Doses Of Iv Bolus Injection Of 24 Iu , Later 8 Iu) (View Interleukin-2 Review and Interleukin-2 Label ).

6587636-7 | Cerebrovascular Spasm, Complicated Migraine, Confusional State, Depressed Level Of Consciousness, Headache, Photophobia, Transient Ischaemic Attack
on Jan 20, 2010 Male patient from AUSTRALIA , 70 years of age, weighting 205.0 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Fludarabine (View Usage). Patient had the following side effects: cerebrovascular spasm, complicated migraine, confusional state, depressed level of consciousness, headache (What is headache?), photophobia, transient ischaemic attack. Fludarabine dosage: . During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), MOCLOBEMIDE (View Moclobemide Review and Moclobemide Label ), BACTRIM (View Bactrim Review and Bactrim Label ), METOCLOPRAMIDE HYDROCHLORIDE (View Metoclopramide Hydrochloride Review and Metoclopramide Hydrochloride Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ), DOLASETRON (View Dolasetron Review and Dolasetron Label ), CELECOXIB (View Celecoxib Review and Celecoxib Label ). Patient was hospitalized.

6579919-1 | Pemphigoid
on Feb 01, 2010 Male patient from UNITED KINGDOM , 51 years of age, was diagnosed with stem cell transplant, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: pemphigoid. Fludarabine dosage: . During the same period patient was treated with ALEMTUZUMAB (View Alemtuzumab Review and Alemtuzumab Label ), BUSULFAN (View Busulfan Review and Busulfan Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6579248-6 | Pemphigoid
Patient was taking Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: pemphigoid on Jan 19, 2010 from UNITED KINGDOM Additional patient health information: Male patient , 51 years of age, was diagnosed with stem cell transplant, prophylaxis against graft versus host disease and. Fludarabine dosage: . During the same period patient was treated with ALEMTUZUMAB (View Alemtuzumab Review and Alemtuzumab Label ), BUSULFAN (View Busulfan Review and Busulfan Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6572466-2 | Pemphigoid
Adverse event was reported on Feb 02, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with stem cell transplant and. Location: UNITED KINGDOM , 51 years of age, Patient had the following side effects: pemphigoid. During the same period patient was treated with ALEMTUZUMAB (View Alemtuzumab Review and Alemtuzumab Label ), BUSULFAN (View Busulfan Review and Busulfan Label ).

6569435-5 | Cerebrovascular Spasm, Complicated Migraine, Confusional State, Depressed Level Of Consciousness, Headache, Photophobia, Transient Ischaemic Attack
on Jan 20, 2010 Male patient from AUSTRALIA , 70 years of age, weighting 205.0 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: cerebrovascular spasm, complicated migraine, confusional state, depressed level of consciousness, headache (What is headache?), photophobia, transient ischaemic attack. Fludarabine dosage: . During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), MOCLOBEMIDE (View Moclobemide Review and Moclobemide Label ), BACTRIM (View Bactrim Review and Bactrim Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ), DOLASETRON (View Dolasetron Review and Dolasetron Label ), CELECOXIB (View Celecoxib Review and Celecoxib Label ). Patient was hospitalized.

6568030-1 | Pemphigoid
on Jan 19, 2010 Male patient from UNITED KINGDOM , 51 years of age, was diagnosed with stem cell transplant, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: pemphigoid. Fludarabine dosage: . During the same period patient was treated with ALEMTUZUMAB (View Alemtuzumab Review and Alemtuzumab Label ), BUSULFAN (View Busulfan Review and Busulfan Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ).

6564941-1 | Sepsis
Patient was taking Fludarabine (View Usage). Patient had the following side effects: sepsis (What is sepsis?) on Jan 20, 2010 from GERMANY Additional patient health information: Female patient , weighting 220.5 lb, was diagnosed with immunosuppression and. Fludarabine dosage: . During the same period patient was treated with TREOSULFAN (View Treosulfan Review and Treosulfan Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6534052-X | Abdominal Pain, Anuria, Blood Amylase Increased, Blood Bilirubin Increased, Blood Creatinine Increased, Multi-organ Failure
Adverse event was reported on Jan 04, 2010 by a Male patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with bone marrow conditioning regimen, infection prophylaxis, prophylaxis of nausea and vomiting, prophylaxis against graft versus host disease and. Location: GERMANY , 56 years of age, weighting 202.8 lb, After Fludarabine was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), anuria, blood amylase increased, blood bilirubin increased, blood creatinine increased, multi-organ failure. During the same period patient was treated with TREOSULFAN (View Treosulfan Review and Treosulfan Label ), AMOXICILLIN AND CLAVULANATE POTASSIUM (View Amoxicillin And Clavulanate Potassium Review and Amoxicillin And Clavulanate Potassium Label ), ACICLOVIR (View Aciclovir Review and Aciclovir Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), FUROSEMIDE (Intake Over Many Month Prior To Hsct) (View Furosemide Review and Furosemide Label ), ALDACTONE (Intake Over Many Month Prior To Hsct) (View Aldactone Review and Aldactone Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), CYCLOSPORINE (Dose Adjusted To Creatinine Levels) (View Cyclosporine Review and Cyclosporine Label ).

6533397-7 | Angiotensin Converting Enzyme Decreased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Fibrosis, Gamma-glutamyltransferase Increased, Granuloma Skin, Granulomatous Liver Disease, Liver Palpable Subcostal, Lung Neoplasm
on Jan 06, 2010 Female patient from UNITED KINGDOM , 45 years of age, was diagnosed with stem cell transplant and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: angiotensin converting enzyme decreased, aspartate aminotransferase increased, blood alkaline phosphatase increased, fibrosis, gamma-glutamyltransferase increased, granuloma skin, granulomatous liver disease, liver palpable subcostal, lung neoplasm. Fludarabine dosage: . During the same period patient was treated with ALEMTUZUMAB (View Alemtuzumab Review and Alemtuzumab Label ), BUSULFAN (View Busulfan Review and Busulfan Label ).

6531319-6 | Abdominal Pain, Anuria, Blood Amylase Increased, Blood Bilirubin Increased, Blood Creatinine Increased, Multi-organ Failure
on Jan 04, 2010 Male patient from GERMANY , 56 years of age, weighting 202.8 lb, was diagnosed with bone marrow conditioning regimen, infection prophylaxis, prophylaxis of nausea and vomiting, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). Patient had the following side effects: abdominal pain (What is abdominal pain?), anuria, blood amylase increased, blood bilirubin increased, blood creatinine increased, multi-organ failure. Fludarabine dosage: . During the same period patient was treated with TREOSULFAN (View Treosulfan Review and Treosulfan Label ), AMOXICILLIN AND CLAVULANATE POTASSIUM (View Amoxicillin And Clavulanate Potassium Review and Amoxicillin And Clavulanate Potassium Label ), ACICLOVIR (View Aciclovir Review and Aciclovir Label ), FLUCONAZOLE (View Fluconazole Review and Fluconazole Label ), FUROSEMIDE (Intake Over Many Month Prior To Hsct) (View Furosemide Review and Furosemide Label ), ALDACTONE (Intake Over Many Month Prior To Hsct) (View Aldactone Review and Aldactone Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), CYCLOSPORINE (Dose Adjusted To Creatinine Levels) (View Cyclosporine Review and Cyclosporine Label ).

6521967-1 | Bone Marrow Failure, Cerebral Toxoplasmosis, Citrobacter Sepsis, Gangrene, Hypogammaglobulinaemia, Molluscum Contagiosum, Pancytopenia, Pseudomonal Sepsis, Streptococcal Infection
Patient was taking Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: bone marrow failure, cerebral toxoplasmosis, citrobacter sepsis, gangrene, hypogammaglobulinaemia, molluscum contagiosum, pancytopenia, pseudomonal sepsis, streptococcal infection (What is streptococcal infection?) on Dec 23, 2009 from UNITED KINGDOM Additional patient health information: Male patient , 57 years of age, was diagnosed with waldenstrom's macroglobulinaemia and. Fludarabine dosage: . During the same period patient was treated with CHLORAMBUCIL (View Chlorambucil Review and Chlorambucil Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), THALIDOMIDE (View Thalidomide Review and Thalidomide Label ).

6520344-7 | Malignant Melanoma
Adverse event was reported on Dec 18, 2009 by a Female patient taking Fludarabine (View Usage) (Dosage: ) was diagnosed with chronic lymphocytic leukaemia, hypercholesterolaemia, hypertension, pain (What is pain?) and. Location: NETHERLANDS , 62 years of age, weighting 202.8 lb, Patient experienced the following unwanted or unexpected effects: malignant melanoma. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), GIMONCOP (View Gimoncop Review and Gimoncop Label ), ENALAPRIL (View Enalapril Review and Enalapril Label ), PINEX (View Pinex Review and Pinex Label ). Patient was hospitalized.

6520316-2 | Renal Failure Acute, Tumour Lysis Syndrome
on Dec 17, 2009 Male patient from GERMANY , weighting 198.4 lb, was diagnosed with chronic lymphocytic leukaemia and was treated with Fludarabine (View Usage). Patient had the following side effects: renal failure acute, tumour lysis syndrome. Fludarabine dosage: Cycle 1. During the same period patient was treated with RITUXIMAB (Cycle 1) (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (Cycle 1) (View Cyclophosphamide Review and Cyclophosphamide Label ), NEUPOGEN (30) (View Neupogen Review and Neupogen Label ). Patient was hospitalized.

6518935-2 | Blood Bilirubin Increased, Clostridium Difficile Colitis, Neutropenic Sepsis, Platelet Count Decreased
on Dec 04, 2009 Female patient from UNITED KINGDOM , 40 years of age, was diagnosed with pancreatic carcinoma metastatic and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: blood bilirubin increased, clostridium difficile colitis, neutropenic sepsis, platelet count decreased. Fludarabine dosage: 48 Mg, Daily, Iv. During the same period patient was treated with CYCLOPHOSPHAMIDE (4500 Mg, Iv) (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6516240-1 | Acute Graft Versus Host Disease, Fluid Retention, Hyperbilirubinaemia, Neutropenia, Thrombocytopenia, Transaminases Increased
Patient was taking Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, fluid retention, hyperbilirubinaemia, neutropenia, thrombocytopenia, transaminases increased on Dec 17, 2009 from JAPAN Additional patient health information: Male patient , 31 years of age, was diagnosed with prophylaxis against graft versus host disease and. Fludarabine dosage: Total Daily Dose: 25 Mg/m2. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN (Total Daily Dose: 6 Mg/m2) (View Gemtuzumab Ozogamicin Review and Gemtuzumab Ozogamicin Label ), MELPHALAN (Total Daily Dose: 40 Mg/m2) (View Melphalan Review and Melphalan Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), LOW MOLECULAR WEIGHT HEPARIN (View Low-molecular-weight Heparin Review and Low-molecular-weight Heparin Label ), PROSTAGLANDIN E1 (View Prostaglandin E1 Review and Prostaglandin E1 Label ), ANTI THROMBIN III (View Anti-thrombin Iii Review and Anti-thrombin Iii Label ).

6516165-1 | Abdominal Pain Upper, Coagulopathy, Hyperbilirubinaemia, Neutropenia, Thrombocytopenia, Transaminases Increased, Venoocclusive Liver Disease
Adverse event was reported on Dec 17, 2009 by a Male patient taking Fludarabine (View Usage) (Dosage: Total Daily Dose: 25 Mg/m2) was diagnosed with acute myeloid leukaemia, prophylaxis against graft versus host disease and. Location: JAPAN , 31 years of age, Patient had the following side effects: abdominal pain upper, coagulopathy, hyperbilirubinaemia, neutropenia, thrombocytopenia, transaminases increased, venoocclusive liver disease. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN (Total Daily Dose: 3 Mg/m2) (View Gemtuzumab Ozogamicin Review and Gemtuzumab Ozogamicin Label ), MELPHALAN (Total Daily Dose: 40 Mg/m2) (View Melphalan Review and Melphalan Label ), ARA C (Day -6 To - 5) (View Ara-c Review and Ara-c Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), LOW MOLECULAR WEIGHT HEPARIN (View Low-molecular-weight Heparin Review and Low-molecular-weight Heparin Label ), PROSTAGLANDIN E1 (View Prostaglandin E1 Review and Prostaglandin E1 Label ).

6516162-6 | Acute Graft Versus Host Disease, Hyperbilirubinaemia, Neutropenia, Pyrexia, Thrombocytopenia, Transaminases Increased, Weight Increased
on Dec 17, 2009 Female patient from JAPAN , 55 years of age, was diagnosed with acute myeloid leukaemia, prophylaxis against graft versus host disease and was treated with Fludarabine (View Usage). After Fludarabine was administered, patient had the following side effects: acute graft versus host disease, hyperbilirubinaemia, neutropenia, pyrexia, thrombocytopenia, transaminases increased, weight increased. Fludarabine dosage: Total Daily Dose: 25 Mg/m2. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN (Total Daily Dose: 6 Mg/m2) (View Gemtuzumab Ozogamicin Review and Gemtuzumab Ozogamicin Label ), MELPHALAN (Total Daily Dose: 40 Mg/m2) (View Melphalan Review and Melphalan Label ), ARA C (As Used: 2 G) (View Ara-c Review and Ara-c Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), LOW MOLECULAR WEIGHT HEPARIN (View Low-molecular-weight Heparin Review and Low-molecular-weight Heparin Label ).

6509487-1 | Blood Bilirubin Increased, Clostridium Difficile Colitis, Diarrhoea, Febrile Neutropenia, Neutropenic Sepsis, Pyrexia, Thrombocytopenia
on Nov 17, 2009 Female patient from UNITED KINGDOM , 40 years of age, was diagnosed with pancreatic carcinoma metastatic, device related infection and was treated with Fludarabine (View Usage). Patient experienced the following unwanted or unexpected effects: blood bilirubin increased, clostridium difficile colitis, diarrhoea, febrile neutropenia, neutropenic sepsis, pyrexia, thrombocytopenia. Fludarabine dosage: 25 Mg/m2. During the same period patient was treated with CYCLOPHOSPHAMIDE (60 Mg/m2/kg) (View Cyclophosphamide Review and Cyclophosphamide Label ), MFEZ T CELLS (View Mfez T Cells Review and Mfez T Cells Label ), PROLEUKIN (45 Miu Decreased Incrementally To 22.5 Miu) (View Proleukin Review and Proleukin Label ), TEICOPLANIN (View Teicoplanin Review and Teicoplanin Label ), MEROPENEM (View Meropenem Review and Meropenem Label ). Patient was hospitalized.

6504878-7 | Vomiting
Patient was taking Fludarabine (View Usage). Patient had the following side effects: vomiting on Nov 30, 2009 from GERMANY Additional patient health information: Female patient , 75 years of age, weighting 147.7 lb, was diagnosed with chronic lymphocytic leukaemia and. Fludarabine dosage: Treatment Days Days 1, 3 And 5 Per Cycle. During the same period patient was treated with MCP (Total Daily Dose: 60 Gtt) (View Mcp Review and Mcp Label ), DILTIAZEM (Total Daily Dose: 180 Mg) (View Diltiazem Review and Diltiazem Label ), DIGITOXIN INJ (View Digitoxin Inj Review and Digitoxin Inj Label ), PENTAERYTHRITOL TETRANITRATE (View Pentaerythritol Tetranitrate Review and Pentaerythritol Tetranitrate Label ), ATACAND (View Atacand Review and Atacand Label ), NEXIUM (View Nexium Review and Nexium Label ). Patient was hospitalized.